Valeant Pharma (VRX) Reports Q3 EPS of $3.69, Beating Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Valeant Announces Third-Quarter 2017 Results
November 7, 2017 7:01 AM ESTLAVAL, Quebec, Nov. 7, 2017 /PRNewswire/ --
Strong Third-Quarter 2017 Financial Results Revenues of $2,219 million GAAP Net Income of $1,301 million Adjusted Net Income (non-GAAP) of $367 million GAAP Cash Flow From Operations of $490 million; Year-to-Date of $1,712 million Adjusted EBITDA (non-GAAP) of $951 million Delivered Strong Organic Growth1 (non-GAAP) in Bausch + Lomb/International Segment and Salix Business Exceeds $5 Billion Debt Reduction Commitment Early Updates 2017 Full-Year Revenue and Maintains Adjusted EBITDA (non-GAAP) Guidance Range Despite Asset DivestituresValeant... More
